CervoMed (CRVO) Capital Expenditures (2010 - 2017)

CervoMed (CRVO) posted Capital Expenditures of $9219.0 for Q4 2017, down 97.54% sequentially from $374602.0 in Q3 2017.

CervoMed (CRVO) Capital Expenditures (2010 - 2017) Analysis & Trends

CervoMed has reported Capital Expenditures for 5 years, with the latest figure at $9219.0 in Q4 2017.

Quarterly Capital Expenditures changed N/A year-over-year to $9219.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $447823.0 (up 19111.63% YoY) and the FY2017 annual result came in at $447823.0, up 19111.63% from the prior year.
Capital Expenditures slipped to $9219.0 in Q4 2017 per CRVO's latest filing, from $374602.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $374602.0 in Q3 2017 and troughed at $337.0 in Q2 2016.
A 3-year average of $49044.5 and a median of $7566.5 in 2015 frame the typical range for Capital Expenditures.
The sharpest annual moves came in 2016 and 2017: Capital Expenditures plunged 96.15% in 2016, then jumped 17000.89% in 2017.
Over 3 years, Capital Expenditures stood at $26647.0 in 2015, then tumbled by 98.74% to $337.0 in 2016, then soared by 2635.61% to $9219.0 in 2017.
According to Business Quant data, Capital Expenditures over the past three periods registered $9219.0, $374602.0, and $57630.0 for Q4 2017, Q3 2017, and Q2 2017 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	CervoMed	26.64 Mn	26.64 Mn	-	-

Download Data